The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Abiraterone acetate (AA) in patients with metastatic castration-resistant prostate cancer (MCRPC) after docetaxel chemotherapy: Multicentric experience of Anatolian Society of Medical Oncology.
Umut Demirci
No relevant relationships to disclose
Utku Oflazoglu
No relevant relationships to disclose
Hilmi Kodaz
No relevant relationships to disclose
Aydin Ciltas
No relevant relationships to disclose
Umut Kefeli
No relevant relationships to disclose
Murat Akyol
No relevant relationships to disclose
Banu Ozturk
No relevant relationships to disclose
Caglayan Geredeli
No relevant relationships to disclose
Mehmet Metin Seker
No relevant relationships to disclose
Sener Cihan
No relevant relationships to disclose
Didem Tastekin
No relevant relationships to disclose
Alper Sevinc
No relevant relationships to disclose
Muhammed Bulent Akinci
No relevant relationships to disclose
Mukremin Uysal
No relevant relationships to disclose
Burcu Yapar Taskoylu
No relevant relationships to disclose
Ayse Ocak Duran
No relevant relationships to disclose
Omer Kamil Yazici
No relevant relationships to disclose
Aziz Karaoglu
No relevant relationships to disclose
Mustafa Benekli
No relevant relationships to disclose
Suleyman Buyukberber
No relevant relationships to disclose